CD274 and neoplasm: Among tumor immunotherapies, immune checkpoint blockade (ICB), particularly the inhibition of PD-1/PD-L1 pathway, has achieved remarkable success by reversing tumor immune suppression and recovering the effector function of exhausted T cells(Barclay et al., 2018; Huynh et al., 2025; Tan et al., 2020).